ProShare Advisors’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $629K | Sell |
24,466
-3,271
| -12% | -$67.2K | ﹤0.01% | 963 |
|
|
2026
Q1 | $533K | Sell |
27,737
-2,945
| -10% | -$58.6K | ﹤0.01% | 1024 |
|
|
2025
Q4 | $507K | Buy |
30,682
+2,827
| +10% | +$47.7K | ﹤0.01% | 1126 |
|
|
2025
Q3 | $404K | Sell |
27,855
-4,727
| -15% | -$67.9K | ﹤0.01% | 1235 |
|
|
2025
Q2 | $456K | Sell |
32,582
-879
| -3% | -$12.4K | ﹤0.01% | 1174 |
|
|
2025
Q1 | $455K | Sell |
33,461
-8,364
| -20% | -$160K | ﹤0.01% | 1145 |
|
|
2024
Q4 | $852K | Buy |
41,825
+9,877
| +31% | +$253K | ﹤0.01% | 983 |
|
|
2024
Q3 | $931K | Buy |
31,948
+7,150
| +29% | +$177K | ﹤0.01% | 838 |
|
|
2024
Q2 | $576K | Sell |
24,798
-6,407
| -21% | -$123K | ﹤0.01% | 906 |
|
|
2024
Q1 | $640K | Buy |
31,205
+2,820
| +10% | +$53K | ﹤0.01% | 954 |
|
|
2023
Q4 | $609K | Buy |
28,385
+4,053
| +17% | +$80.3K | ﹤0.01% | 932 |
|
|
2023
Q3 | $502K | Buy |
24,332
+109
| +0.4% | +$2.77K | ﹤0.01% | 912 |
|
|
2023
Q2 | $715K | Buy |
24,223
+1,937
| +9% | +$54.5K | ﹤0.01% | 808 |
|
|
2023
Q1 | $513K | Sell |
22,286
-4,622
| -17% | -$127K | ﹤0.01% | 901 |
|
|
2022
Q4 | $748K | Buy |
26,908
+4,119
| +18% | +$123K | ﹤0.01% | 806 |
|
|
2022
Q3 | $700K | Buy |
22,789
+615
| +3% | +$20K | ﹤0.01% | 796 |
|
|
2022
Q2 | $653K | Sell |
22,174
-9,707
| -30% | -$254K | ﹤0.01% | 863 |
|
|
2022
Q1 | $1.03M | Sell |
31,881
-7,521
| -19% | -$259K | ﹤0.01% | 913 |
|
|
2021
Q4 | $1.76M | Sell |
39,402
-435
| -1% | -$20.6K | ﹤0.01% | 797 |
|
|
2021
Q3 | $2.01M | Sell |
39,837
-5,525
| -12% | -$311K | 0.01% | 712 |
|
|
2021
Q2 | $3.56M | Buy |
45,362
+11,785
| +35% | +$729K | 0.01% | 571 |
|
|
2021
Q1 | $1.92M | Buy |
33,577
+1,139
| +4% | +$76.2K | 0.01% | 712 |
|
|
2020
Q4 | $2.72M | Buy |
32,438
+7,651
| +31% | +$463K | 0.01% | 566 |
|
|
2020
Q3 | $888K | Sell |
24,787
-637
| -3% | -$19.2K | ﹤0.01% | 754 |
|
|
2020
Q2 | $615K | Buy |
25,424
+9,145
| +56% | +$215K | ﹤0.01% | 862 |
|
|
2020
Q1 | $285K | Sell |
16,279
-10,987
| -40% | -$229K | ﹤0.01% | 891 |
|
|
2019
Q4 | $475K | Sell |
27,266
-4,124
| -13% | -$68.6K | ﹤0.01% | 1086 |
|
|
2019
Q3 | $481K | Sell |
31,390
-1,299
| -4% | -$24.8K | ﹤0.01% | 999 |
|
|
2019
Q2 | $679K | Sell |
32,689
-4,522
| -12% | -$101K | ﹤0.01% | 901 |
|
|
2019
Q1 | $864K | Buy |
37,211
+226
| +0.6% | +$4.73K | 0.01% | 830 |
|
|
2018
Q4 | $764K | Buy |
+36,985
| New | +$671K | 0.01% | 789 |
|
Other funds holding DNLI
ProShare Advisors's DNLI Position: Q2 2026 in Review
ProShare Advisors reduced its Denali Therapeutics (DNLI) stake by 12% in Q2 2026, selling an estimated $67.2K and leaving 24,466 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #963.
ProShare Advisors first reported a position in DNLI in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.56M in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- ProShare Advisors held 24,466 shares of Denali Therapeutics worth $629K as of Q2 2026.
- ProShare Advisors sold 3,271 Denali Therapeutics shares in Q2 2026, an estimated $67.2K.
- Denali Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #963 holding.
- ProShare Advisors first reported a position in Denali Therapeutics in Q4 2018 and has held it in 31 quarters since.
- ProShare Advisors's Denali Therapeutics position peaked at $3.56M in Q2 2021.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.